IMVAQ Therapeutics Alternatives & Competitors

12 companies similar to IMVAQ Therapeutics

Surface Oncology Inc.

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2...

14 Post-IPO Equity $88.90M

Cambridge, United States

Biotechnology Health Care +1

INmune Bio Inc.

INmune Bio is focused on modulating components of the innate immune system to activate an...

23 Post-IPO Equity $112.91M

Boca Raton, United States

Biotechnology Industrial

Imugene Limited

Bringing Effective New Treatments And Options To Patients Who Need Them

26 IPO $129.52M

Australia

Biotechnology Health Care

NextCure, Inc.

49 Post-IPO Equity $310.00M

Beltsville, United States

Biopharma Biotechnology +1

Rival Readout

Competing with IMVAQ Therapeutics? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout

iTeos Therapeutics

Cancer Immunotherapies by Design

186 Post-IPO Equity $362.74M

Cambridge, United States

Biotechnology Health Care

NeoPhore Ltd

Discovering drugs that create neoantigens

18 Series B $33.80M

Cambridge, United Kingdom

Biotechnology Health and Wellness

Tizona Therapeutics, Inc.

Harnessing the power of the immune system to develop treatments for cancer.

23 $343.00M

South San Francisco, Unit...

Biotechnology

TME Pharma

Developing novel therapies for treatment of the most aggressive cancers by acting on the t...

12 Post-IPO Equity $138.73M

Berlin, Germany

Biotechnology Health Care +1

ALX Oncology

ALX Oncology is a clinical-stage biotechnology company advancing cancer therapies by boost...

63 IPO $525.20M

South San Francisco, Unit...

Biopharma Biotechnology +3

Lytix Biopharma

A clinical-stage immuno-oncology company developing proprietary oncolytic drugs as a novel...

15 Grant $24.70M

Oslo, Norway

Biotechnology Health Care +1

Nectin Therapeutics

Unlocking the power of the immune system - next-generation immunotherapy

12 Venture round $46.40M

Jerusalem, Israel

Biotechnology Life Sciences

ImmunoGenesis, Inc.

Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mech...

14 Venture round $28.00M

Houston, United States

Biotechnology Health Care +2

About IMVAQ Therapeutics

IMVAQ Therapeutics is a biotechnology startup founded in 2018 in the United States that is focused on developing innovative immuno-oncologics for the treatment of metastatic cancer. Leveraging the research of its distinguished scientific founders at Memorial Sloan Kettering Cancer Center, a renowned clinical and R&D ca...

Business keywords

Immuno-oncologics, Metastatic Cancer, Therapeutic Products, Immune System, Innovation, Oncology, Clinical, R&D, Cancer Treatment, Memorial Sloan Kettering Cancer Center, Scientific Founders, Immune Response, Tumor Eradication

Frequently Asked Questions

Companies similar to IMVAQ Therapeutics include Surface Oncology Inc., INmune Bio Inc., Imugene Limited, NextCure, Inc., iTeos Therapeutics. They work in Biotechnology and share IMVAQ Therapeutics's focus on cancer treatment, immune system and oncology.

Bounce Watch lists 12 companies that share IMVAQ Therapeutics's industries and are closest to it in business tags, services, target customers, business model and size.

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around IMVAQ Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Book a 7-day Readout Get a free snapshot

Explore Related

IMVAQ Therapeutics Profile Surface Oncology Inc. Alternatives Imugene Limited Alternatives NextCure, Inc. Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at IMVAQ Therapeutics on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.